X

Drug Profile

NPI 002

Alternative Names: NPI-002

Latest Information Update: 29 Mar 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nacuity Pharmaceuticals
Class Eye disorder therapies; Small molecules
Mechanism of Action Antioxidants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Cataracts

Most Recent Events

27 Jan 2022 Phase-I/II clinical trials in Cataracts (Prevention, In the elderly) in Australia (Intravitreous) (NCT05026632)
14 Sep 2021 Nacuity Pharmaceuticals plans a phase I/IItrial for Cataracts in October 2021 (Intravitreal) (NCT05026632)
31 Mar 2021 Nanoform and Nacuity Pharmaceuticals agree to co-develop N-acetylcysteine-amide in Finland for Cataracts

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com